necitumumab

01/01/2018 - "The safety and efficacy of necitumumab has been evaluated in two-phase III clinical trials, one demonstrating a lack of efficacy in non-squamous non-small cell lung cancer and another demonstrating improvement in overall survival and progression-free survival in squamous cell non-small cell lung cancer. "
06/01/2018 - "The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. "
02/01/2016 - "Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?"
03/01/2019 - "Necitumumab for the treatment of advanced non-small-cell lung cancer."
01/01/2018 - "Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies."

08/01/2018 - "Necitumumab: a new option for first-line treatment of squamous cell lung cancer."
10/01/2019 - "The safety profile was fairly comparable with previous necitumumab combination studies in lung cancer."
12/01/2015 - "Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost."
12/01/2014 - "Necitumumab: a new therapeutic option for squamous cell lung cancer?"
01/01/2018 - "In the SQUIRE trial, the addition of necitumumab to chemotherapy for squamous cell lung cancer significantly improved overall survival (OS) (hazard ratio [HR] = 0.84); in a post hoc analysis, EGFR copy number gain determined by fluorescence in situ hybridization (FISH) showed a trend toward improved OS (HR = 0.70) and progression-free survival (PFS) (HR = 0.71) with the addition of necitumumab. "

11/01/2016 - "Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors."
08/01/2016 - "The primary objective of this phase 2 study, conducted in accordance with International Conference on Harmonisation E14 guidance, was to determine the effect of necitumumab treatment on QT/QTc interval in patients with advanced solid tumors. "
01/01/2017 - "Population Pharmacokinetics of Necitumumab in Cancer Patients."
08/01/2016 - "The results demonstrate lack of effect of necitumumab on the QTc interval in heavily pretreated patients with advanced solid tumors, suggesting that QT prolongation is not a major safety concern for necitumumab at the recommended therapeutic dose. "
08/01/2016 - "Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors."

02/16/2016 - "Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer."
02/01/2016 - "Necitumumab was also under phase II development for colorectal cancer in Belgium and Spain; however, no recent development has been reported for this indication. "
02/16/2016 - "This single-arm phase II study investigated the EGFR monoclonal antibody necitumumab plus modified FOLFOX6 (mFOLFOX6) in first-line treatment of locally advanced or metastatic colorectal cancer (mCRC). "

10/01/2013 - "Combined with an additional cell-based ELISA screen, a novel scFv, E10, was obtained with two-fold more potent on the binding to EGFR-bearing tumor cells (the epidermoid carcinoma cell line A431) and the inhibition of A431 cells proliferation than scFv 11F8, suggesting that the E10 has the potential to be developed as therapeutic agents to solid tumors associated with EGFR overexpression."
01/01/2023 - "The efficacy and safety of the anti-EGFR antibody necitumumab combined with gemcitabine and cisplatin (N + GC) in the first-line treatment of advanced lung squamous cell carcinoma (LSCC) have been proven. "
01/01/2023 - "Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma."
12/01/2023 - "Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). "
01/01/2021 - "Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report."